Wire · operational-macro
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 November 2026 · Fusion42 review
Enliven Therapeutics has reached alignment with the FDA on the final design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia and expects to start the trial before the end of 2026. The company holds $884 million in cash, supporting operations into 2030, and reported increased R&D and administrative expenses with a $27.7 million net loss for Q3 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clear opening in CML drug development as FDA alignment clears trial design hurdles. Use this moment to secure partnerships that can amplify relcobatinib's launch and fill the gap left by existing therapies.
◆ Coverage
1 source · 5 Nov 2026
◆ Related on Wire
◆ Topics